Platform for Biomarkers
The Platform for Biomarkers offers three complementary immunoassay technologies to enable highly sensitive, multiplexed and robust detection of protein biomarkers across a wide dynamic range:
- Single Molecule Array (SIMOA – Quanterix HD-X)
- Multiplex ultrasensitive immunoassays (Luminex® xMAP® / Intelliflex)
- Standard high-quality ELISA assays
Each technology provides unique analytical capabilities, allowing users to tailor detection strategies according to the required sensitivity, sample volume, dynamic range, and number of analytes.
1. SINGLE MOLECULE ARRAY (SIMOA) – Ultra sensitive digital immunoassays
Our Quanterix SIMOA HD-X analyzer is a fully automated platform based on Single Molecule Array (SIMOA) technology, a digital version of ELISA. Individual immunocomplexes formed on paramagnetic beads are isolated and sealed in thousands of femtoliter-sized microwells on SIMOA discs, enabling digital counting of single protein molecules.
This digital detection format provides up to 1000-fold higher sensitivity than conventional immunoassays, enabling precise quantification of extremely low-abundance protein biomarkers and supporting precision medicine applications.
Main technical specifications
- Throughput: 3 plates per 8-hour shift (~300 datapoints/day)
- Fully automated workflow (plate or tube format)
- Total assay time < 2.5 h per 96‑well plate
- Hands‑on/startup time < 20 min
- Sample input: 96‑well plate or tubes
- Sample volume: 1 µL–100 µL
- Multiplexing: up to 4‑plex
Benefits
- Ultra-sensitivity: detect proteins at fg/mL levels
- Automation: highly reproducible, sample-to-answer workflow
- Multiplexing: up to 4 biomarkers in a single sample
- Flexibility for high-throughput or fast‑turnaround workflows
- Efficiency: stable calibration and consistent assay conditions
2. Luminex® INTELLIFLEX – Multiplex quantitative immunoassays
The platform incorporates Luminex® xMAP® / Intelliflex technology, enabling ultrasensitive multiplex detection of multiple analytes simultaneously using color-coded microspheres.
This method allows simultaneous quantification of up to 50+ analytes in a single well, making it ideal for cytokine panels, signaling molecule profiling, and broad biomarker discovery studies.
Key features
- High‑multiplexing: 10–50+ biomarkers per sample
- Low sample consumption: typically, 25–50 µL
- Flexible assay design: customizable multiplex panels
- Broad dynamic range and robust quantification
3. Standard ELISA – Robust single analyte quantification
The platform also offers classical ELISA assays, providing accessible, reliable, and cost-effective detection for single biomarkers.
Standard ELISA remains the gold standard for many clinical and research applications due to its high specificity, straightforward workflow, and excellent reproducibility.
Key features
- High sensitivity and specificity for individual analytes
- Ideal for validation of biomarker candidates
- Compatible with a wide variety of commercial kits
SELECTED PUBLICATIONS OF THE PLATFORM
- Hexaraphane as a potential therapeutic strategy for tauopathies Redox Biology, 2026. DOI: 10.1016/j.redox.2026.104107
- Influence of Lifestyle on Brain Sensitivity to Circulating Insulin-like Growth Factor 1 Mol Sci, 2025. DOI: 10.3390/ijms262010008.
- Stepwise approach to alzheimer’s disease diagnosis in primary care using cognitive screening, risk factors, neuroimaging and plasma biomarkers Scientific Reports, 2025. DOI: 10.1038/s41598-025-17394-3
- Assessment of the Correlation and Diagnostic Accuracy between Cerebrospinal Fluid and Plasma Alzheimer’s Disease Biomarkers: A Comparison of the Lumipulse and Simoa Platforms International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms25094594
- Serum assessment of traumatic axonal injury: the correlation of GFAP, t-Tau, UCH-L1, and NfL levels with diffusion tensor imaging metrics and its prognosis utility J Neurosurg, 2023. DOI: 10.3171/2022.5.JNS22638
- New, Fully Implantable Device for Selective Clearance of CSF-Target Molecules: Proof of Concept in a Murine Model of Alzheimer’s Disease International Journal of Molecular Sciences, 2022. DOI: 10.3390/ijms23169256
- Linking Plasma Amyloid Beta and Neurofilament Light Chain to Intracortical Myelin Content in Cognitively Normal Older Adults Frontiers in Aging Neuroscience, 2022. DOI: 10.3389/fnagi.2022.896848
- Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers Parkinsonism Relat Disord, 2022. DOI: 10.1016/j.parkreldis.2022.01.024
- Whole Blood Expression Pattern of Inflammation and Redox Genes in Mild Alzheimer’s Disease Journal of Inflammation Research, 2021. DOI: 10.2147/JIR.S334337